Search | Clinical Trials Finder

Conditions: HIV-1-infection
Interventions: GS-1219, BVY, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: HIV-1-infection
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC); Drug
Lead sponsor: The Crofoot Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1 Infection
Interventions: FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more

Conditions: HIV/AIDS, Contraception
Interventions: tenofovir/emtricitabine, DMPA; Combination Product · Drug
Lead sponsor: Sharon Achilles; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infection
Interventions: Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 94
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more

Conditions: HIV Infection
Interventions: FTC/TDF (Truvada®); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 22 Years · Male only
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 51
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 79
States / cities: Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more

Conditions: HIV, HBV
Interventions: E/C/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more

Conditions: HIV-1-infection
Interventions: B/F/TAF; Drug
Lead sponsor: Tulika Singh, MD; Other
Eligibility: 65 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Palm Springs, California

Conditions: HIV Infection
Interventions: 3MV, PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®)); Behavioral · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 22 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: HIV-1-infection
Interventions: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: HIV-1 Infection
Interventions: B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 38
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: HIV-1 Infection
Interventions: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more

Conditions: HIV-1-infection
Interventions: B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more

Conditions: HIV-1 Infection, HCV Infection
Interventions: E/C/F/TAF, F/R/TAF, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: HIV-1/HBV Co-Infection
Interventions: B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more

Conditions: HIV-1 Infection
Interventions: RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 63
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions: ISL, ULO, BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more

Conditions: HIV, HIV Infections
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: NNRTI, FTC/TDF, Stribild; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 39
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more

Search by objective public record fields.

Study of GS-1219 in Participants With HIV-1

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients